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ABSTRACT
The correction of specific signaling defects can reverse the oncogenic 
phenotype of tumor cells by acting in a dominant manner over the cancer genome. 
Unfortunately, there have been very few successful attempts at identifying the 
primary cues that could redirect malignant tissues to a normal phenotype. Here we 
show that suppression of the lipogenic enzyme fatty acid synthase (FASN) leads 
to stable reversion of the malignant phenotype and normalizes differentiation in a 
model of breast cancer (BC) progression. FASN knockdown dramatically reduced 
tumorigenicity of BC cells and restored tissue architecture, which was reminiscent 
of normal ductal-like structures in the mammary gland. Loss of FASN signaling was 
sufficient to direct tumors to a reversed phenotype that was near normal when 
considering the development of polarized growth-arrested acinar-like structure 
similar to those formed by nonmalignant breast cells in a 3D reconstituted basement 
membrane in vitro. This process, in vivo, resulted in a low proliferation index, 
mesenchymal-epithelial transition, and shut-off of the angiogenic switch in FASN-
depleted BC cells orthotopically implanted into mammary fat pads. The role of FASN 
as a negative regulator of correct breast tissue architecture and terminal epithelial cell 
differentiation was dominant over the malignant phenotype of tumor cells possessing 
multiple cancer-driving genetic lesions as it remained stable during the course of 
serial in vivo passage of orthotopic tumor-derived cells. Transient knockdown of 
FASN suppressed hallmark structural and cytosolic/secretive proteins (vimentin, 
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INTRODUCTION
The aberrant oncogenic phenotype of tumor cells 
can revert to a normalized, non-malignant state without 
necessarily correcting the cancer-driving genomic 
abnormalities [1–6]. Even when genetic abnormalities 
elicit defects in the stem cell-like population, driving 
tumor maintenance and metastasis, these life-threatening 
cells do not always lose their ability to undergo 
differentiation [7]. Studies with myeloid leukemia 
cells have shown that the epigenetic reprogramming of 
malignant cells, by inducing differentiation, can efficiently 
bypass cancer-driving genetic abnormalities [8–11]. The 
therapeutic paradigm of differentiation therapy as a valid 
approach for “phenotypic reversion” in the treatment of 
cancer patients is exemplified by the successful use of 
all-trans retinoic acid (ATRA) as the regimen of choice 
for treatment of acute promyelocytic leukemia (APL). 
Nevertheless, beyond the occurrence of complete 
remissions in patients with APL treated with ATRA, there 
have been very few successful attempts at identifying the 
signaling defects that, once corrected, might successfully 
favor the process of halting malignancy by overriding the 
genetic abnormalities in tumor cells. However, interest 
and application of differentiation-based therapy as a viable 
treatment modality for the clinical management of solid 
malignancies have lagged mostly due to deficiencies in 
our understanding of differentiation pathways in solid 
malignancies. It therefore remains an urgent task of cancer 
researchers to identify the primary signaling transduction 
pathways whose normalization would lead to reversions 
of the malignant phenotype for the most common types of 
human carcinomas. 
Cancer is beginning to be understood as a disease 
of reprogramming that involves the progressive resetting 
of the metabolic infrastructure and metabolite levels 
concomitantly with changes in cellular differentiation 
[12–18]. Modulation of metabolism and associated 
signaling is increasingly postulated to be vital in the 
determination of cell identity during oncogenesis, i.e., 
metabolism per se can dictate cancer cell fate decisions 
and differentiation outcomes. Because activation of 
fatty acid synthase (FASN), a key lipogenic enzyme 
catalyzing the terminal steps of de novo fatty acid (FA) 
biogenesis, is an early and near universal hallmark of most 
human carcinomas and their precursor lesions [19–25], 
we hypothesized that the correction of exacerbated 
endogenous lipogenesis might be sufficient to stably 
revert the malignant phenotype. We provide evidence that 
the sole correction of exaggerated lipogenesis leads to a 
stable phenotypic reversion and normalized differentiation 
of malignant tissue by acting in a dominant manner over 
the unstable cancer genome in a model of breast cancer 
(BC) progression. The discovery of FASN signaling 
as a hitherto unrecognized organizer of breast tissue 
architecture can provide new therapeutic avenues aimed 
to chronically restrain the life-threatening potential of 
invasive carcinomas by using FASN-based differentiation 
therapies. 
RESULTS
FASN expression status correlates with the 
malignant phenotype during BC progression
We took advantage of a powerful model of 
multiple cancer cell lines derived from the spontaneously 
immortalized mammary epithelial MCF10A cell line. 
The MCF10A progression series, including MCF10A 
untransformed cells, MCF10AneoT and MCF10AT non-
malignant cells, MCF10DCIS.com ductal carcinoma 
in situ cells and MCF10Ca1a, Ca1d and Ca1h 
malignant cell lines, covers the entire spectrum of 
BC progression, ranging from non-transformed 
breast epithelial cells to metastatic BC cells [26–28]. 
Strikingly, the increase in the tumorigenic and 
invasive potential of MCF10A-derived BC series 
positively correlated with an incremental increase in 
the expression levels of FASN protein (Figure 1A), 
suggesting that up-regulation of FASN-dependent 
endogenous lipogenesis accompanies aggressiveness in 
BC phenotypes. The highly aggressive and metastatic 
cell lines CA1a and CA1d (short for MCF10A-CA1a 
and MCF10A-CA1d, respectively) showed the greatest 
expression of FASN protein (Figure 1A). These in vitro 
findings are in accordance with previous clinical studies 
demonstrating that FASN expression increases as BC 
progresses towards more advanced stages. 
We tested if FASN acts as a metabolic oncogene 
capable of inducing transformation of breast epithelial 
cells. We first examined the sensitivity of immortalized but 
otherwise normal MCF10A cells to FASN inhibitors [29]. 
Neither cerulenin nor C75 significantly affected viability 
of MCF10A cells (Figure S1A, S1B). MCF10A cells 
engineered to stably overexpress FASN (MCF10A/FASN 
cells, Figure S1C) demonstrated a significantly augmented 
N-cadherin, fibronectin) in a model of EMT-induced cancer stem cells (CSC). Indirect 
pharmacological inhibition of FASN promoted a phenotypic switch from basal- to luminal-
like tumorsphere architectures with reduced intrasphere heterogeneity. The fact that sole 
correction of exacerbated lipogenesis can stably reprogram cancer cells back to normal-
like tissue architectures might open a new avenue to chronically restrain BC progression 
by using FASN-based differentiation therapies.
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proliferation capacity (Figure S1E) and, more importantly, 
gained the capacity for anchorage-independent growth 
in soft agar (Figure S1F). Additionally, MCF10A/FASN 
cells were remarkably sensitive to the FASN inhibitor 
C75 compared with MCF10A parental cells (Figure S1D). 
Collectively, these findings, strongly support the 
notion that overexpression of FASN contributes to the 
development of the malignant phenotype during BC 
progression. 
To further evaluate the involvement of FASN during 
BC progression, we monitored the impact of FASN 
pharmacological inhibition on cell viability of the most 
malignant and aggressive cell lines from the MCF10A 
series. In contrast to MCF10A parental cells, the aggressive 
derivatives obtained from xenograft-passaging in nude 
mice [30], CA1a and CA1d, were exquisitely sensitive to 
low concentrations of FASN inhibitors as demonstrated 
by a decrease in cell viability (Figure 1B) and a reduction 
in anchorage-independent growth (Figure 1C, 1D). Cells 
depleted for FASN protein using various lentiviral vectors 
encoding shRNAs specific for the FASN gene (Figure 1E) 
largely recapitulated the growth phenotype of CA1d 
cells treated with pharmacological FASN inhibitors 
(Figure 1F, 1G). Moreover, stable shRNA-mediated 
depletion of FASN reproduced the previously described 
ability of pharmacological FASN inhibitors to significantly 
perturb the cellular energy status, leading to the AMPK-
related phosphorylation and inactivation of acetyl 
coenzyme A carboxylase (ACC) [31] (Figure 1H, 1I).
To question whether FASN inhibition was 
responsible for the growth phenotype of FASN-depleted 
aggressive BC cells, we reevaluated their cell proliferation 
capacity in the presence of palmitate, the product of 
FASN action. Exogenously added palmitate noticeably 
restored cell viability of FASN-depleted CA1d cells 
in a dose-dependent manner (Figure 1J). Furthermore, 
pharmacological blockade of FASN activity failed to 
further inhibit the growth of FASN-depleted CA1d cells 
(Figure S2A, S2B), thus confirming that FASN knockdown 
efficiently normalized the aberrant proliferation driven by 
overexpression of FASN in CA1d parental cells. 
Suppression of FASN-driven endogenous 
lipogenesis restores a non-malignant phenotype 
to aggressive BC cells in vitro
Profound morphological differences were observed 
between FASN-depleted and FASN-overexpressing 
CA1d parental cells after culture for 10 days in a 3D 
reconstituted basement membrane [32–34] (Figure S3A). 
Accordingly, CA1d control cells formed large, loosely 
organized colonies similar to those formed by primary 
tumor cells [33]. The failure of CA1d cells to undergo 
normal morphogenesis in basement membrane was also 
demonstrated by their compromised degree of cell-cell 
adhesion as shown by the absence of lateral staining of 
the epithelial marker E-cadherin (Figure S3A, top) and 
by an increased cytoplasmic localization of E-cadherin 
(cell fractionation studies; not shown). Interestingly, upon 
closer inspection, FASN-depleted CA1d cells appeared 
to have truly reverted to a “non-malignant” phenotype 
(Figure S3A, bottom). Thus, after 10 days in Matrigel, 
CA1D/FASN shRNA#28 cells underwent morphogenesis 
and formed small, highly organized acini reminiscent of 
those formed by cells from reduction mammoplasty [33]. 
Nevertheless, CA1d and CA1D/FASN shRNA#28 cells 
expressed essentially the same levels of E-cadherin 
(Figure S3B), suggesting that normalization of the 
malignant phenotype in FASN-depleted CA1d cells 
was associated with a correct re-assembly of adherent 
junctions rather than with significant up-regulation of cell 
adhesion proteins. The mesenchymal markers vimentin 
and N-cadherin, however, were decreased in FASN-
depleted CA1d cells when compared with CA1d parental 
cells (Figure S3B). 
FASN inhibition promotes normalized 
differentiation of metastatic BC cells in vivo
We next explored whether these findings had 
relevance to tumor formation in vivo. We injected tumor 
cells into the mammary fat pad of athymic nude mice and 
monitored tumor volume for several weeks (Figure 2A–
2C; Figure S4A, S4B). CA1d control cells formed rapidly 
growing tumors, reaching volumes greater than 1500 
mm3 36 days after injection (Figure 2A–2C). In marked 
contrast, two independent FASN-depleted CA1d cell 
clones produced very small nodules with a volume of less 
than 100 mm3 in all injected sites 45 days after injection 
(Figure 2A–2C; Figure S4A, S4B). 
Because the above data strongly suggested that 
normalization of the tumor cell phenotype in vitro was 
complemented in vivo, where the malignant potential is 
drastically reduced or completely lost, we performed a 
careful pathological examination of CA1d- and CA1D/
FASN shRNA#28-derived tumors. Histopathological 
analyses revealed that FASN knockdown shifted the 
differentiation pattern of cancer tissues from an aggressive, 
mesenchymal-like phenotype in CA1d tumors to a highly 
differentiated, epithelial-like phenotype in FASN-depleted 
CA1d lesions (Figure 2D–2G). Whereas the high-grade 
tumors derived from FASN-positive CA1d control 
cells were large and pleomorphic with sheets of poorly 
differentiated cells forming nests, the lesions derived from 
FASN depleted-CA1d cells consistently displayed very 
small, low grade well-differentiated tissues resembling 
the normal glandular structure of the breast (Figure 2D). 
The tissue architecture developing from CA1d- and 
CA1D/FASN shRNA#28 cells was re-evaluated by FISH to 
unambiguously prove that the ductal-like structures arising 
from suppression of FASN were of human origin. Human 
genomic FISH confirmed that FASN-overexpressing 
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CA1d-derived tumors truly represented invasive human 
carcinomas, whereas the tumor tissues from FASN-
depleted CA1d cells almost exclusively represented the 
normal duct-lobular system of the breast (Figure 2E). 
Assessment of the expression and localization of smooth 
muscle actin (SMA), a sensitive and specific myoepithelial 
marker commonly employed to facilitate the identification 
of basal-like tumors [35, 36], revealed a prominent 
distribution of SMA within the invasive carcinoma 
tissue of CA1d tumors (Figure 2F). FASN-depleted 
tissues, however, displayed SMA-positive myoepithelial 
cells surrounding a hollow lumen, a well recognized 
feature of normal ductal-lobular structures (Figure 2F). 
Consistent with the in vitro analysis (Figure S3), 
expression of the mesenchymal marker vimentin was 
suppressed in CA1D/FASN shRNA#28 cancer tissues, 
Figure 1: FASN expression correlates with malignant progression of MCF10CA cells. (A) Western blot analysis of FASN 
protein in cells from various tumor stages. NeoT: neoplasmic, kcl2: atypical hyperplasia, AT1: hyperplasia, DCIS: ductal carcinoma 
in situ, CA: metastatic/invasive cancer. (B) Inhibition of FASN reduces cell viability. CA1d and CA1a cells were treated with cerulenin or 
C75 and cell viability was assessed by MTT reduction. Dose–response curves were plotted as percentages of the control cells’ absorbance 
(= 100%). Results from one representative experiment are presented as mean ± SD; p ≤ 0.02 for cerulenin and p ≤ 0.05 for C75, respectively. 
(C) FASN inhibition impairs anchorage-independent growth. CA1d and CA1a cells were grown in soft agar in the presence of increasing 
concentrations of cerulenin for 21 d. Colony numbers from one representative image are shown as mean ± SD; *p < 0.05. (D) Representative 
images from a soft agar growth assay as described in C. (E) FASN knockdown efficiency in stably-transduced CA1d cells; WT = wild type. 
(F) Depletion of FASN decreases cell viability. Control or FASN-depleted cells were assessed by MTT reduction 72 h post transfection and 
the results from one representative experiment are presented as mean ± SD; *p ≤ 0.05. (G) FASN depletion inhibits anchorage-independent 
growth. FASN-depleted or control CA1d cells were grown in soft agar and colony numbers from one representative experiment are plotted 
as mean ± SD, *p < 0.01. (H) Inhibition of FASN increases the levels of energy stress markers. CA1d cells were treated with either cerulenin 
or C75 and cell lysates were subjected to western blotting. Note a substantial increase in p-AMPK and p21 upon FASN inhibition. (I) 
Depletion of FASN increases the levels of energy stress markers. Control and FASN-depleted CA1d cells were lysed and subjected to 
western blotting. (J) Palmitate increases cell viability of FASN-depleted cells. CA1d/vector control or FASN-depleted cells were exposed 
to increasing concentrations of palmitate-BSA in 0.5% HS containing medium and cell viability was assessed by MTT reduction 72 h after 
treatment. Data are presented as mean ± SD from two independent experiments.
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Figure 2: FASN knockdown in CA1d cells impairs tumor outgrowth and induces a dormant-like phenotype. (A) FASN 
depletion inhibits tumor growth in an orthotopic model. Control (CA1d/vector control) and FASN-depleted cells (CA1d/FASN shRNA #28), 
injected into the fat pad of the mouse mammary gland, were monitored over the course of 7 weeks and tumor growth was assessed twice 
weekly. Tumor growth from one representative experiment out of three independent experiments, with similar results, is presented as 
mean ± SD. (B) FASN depletion decreases tumor volume. Distribution of tumor sizes from control and FASN-knockdown cells at 14, 25, and 
36 days after injection. Note that only extremely small tumors were observed in FASN-depleted cells. Results are presented as mean ± SD 
(n = 12); p < 0.001. (C) Representative images of tumors originating from control and FASN-depleted cells in mice 6 weeks post injection. 
(D) Depletion of FASN restores a non-malignant, dormant-like, phenotype in CA1d cells. Histology of tumors derived from control 
(CA1d/vector control) and FASN-knockdown (CA1d/FASNshRNA#28) cells. Paraffin-embedded tumor sections were stained for H&E 
and FASN. Note the nearly normal looking ducts in the FASN-depleted cells. (E) Ducts from tumor-derived FASN-depleted cells are of 
human origin. Fluorescently labeled human (green) and mouse (red) home-brew whole genomic FISH probes were used to distinguish 
human and murine cells. (F) Visualization of invasive breast tumor cells by staining with smooth muscle actin (SMA, red) and fatty acid 
synthase (FASN, green). Note that in FASN-depleted tissues, a SMA-positive monolayer of cells surrounds a hollow lumen, while it is 
distributed within the tumor in control tissue. (G) FASN depletion reduces cell proliferation and reverses the aggressive tumor phenotype. 
Note high expression of vimentin, a marker for aggressive invasive tumors in control tumors, but not in tumors from FASN-depleted cells.
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while E-cadherin levels were increased (Figure 2G), 
suggesting that loss of FASN imposes mesenchymal-
like BC tissues to undergo the inverse plastic change that 
generates epithelial tissue, the so-called mesenchymal-
epithelial transition (MET).
Loss of FASN leads to a stable tumor reversion
During the histopathological analysis, we observed 
that the percentage of Ki67-positive cells in the epithelial 
structures in FASN-depleted tissues was drastically lower 
than in FASN-overexpressing CA1d-derived invasive 
tumors (Figure 2G). These findings correlate well with the 
hypothesis that normal breast epithelial cells significantly 
reduce their proliferation rate after the formation of 
polarized alveoli and ducts, whereas primary BC cells 
and tumorigenic BC lines form large, disorganized and 
non-polarized colonies that fail to undergo growth arrest 
[32, 34, 37]. The recruitment of new blood supply is a 
rate-limiting step in tumor progression. Given that earlier 
studies in a 3-D model of breast carcinogenesis revealed 
that disorganized, proliferative transformed breast 
epithelial cells show significantly higher expression of 
angiogenic genes compared with their polarized, growth-
arrested nonmalignant counterparts [38], we hypothesized 
that if FASN-dependent endogenous lipogenesis operates 
as a bona fide organizer of breast tissue architecture, FASN 
overexpression should activate the angiogenic switch, even 
in the absence of hypoxia. Conversely, FASN suppression 
should reduce the expression of angiogenic factors and the 
recruitment of endothelial cells (EC) to levels found in 
quiescent nonmalignant epithelium. Accordingly, FASN 
knockdown resulted in a significant down-regulation in the 
secretion of vascular endothelial growth factor (VEGF), 
a potent angiogenic factor, in CA1d cells (Figure 3A). 
Immunohistochemical assessment of CD34, an endothelial 
antigen commonly used to highlight the microvasculature 
vessel density (MVD) as a direct marker of the degree of 
neoangiogenesis, confirmed a markedly reduced capability 
of FASN-depleted tissues to recruit CD34+ EC compared 
with control CA1d-derived tumors (Figure 3B, 3C). 
In contrast, forced expression of FASN significantly 
increased VEGF production in MCF10A cells (Figure 3D). 
Taken together, these findings are consistent with a 
mechanistic scenario in which, in the absence of FASN-
catalyzed endogenous lipogenesis, breast epithelial cells 
might not retain sufficient cellular plasticity and will revert 
from an invasive phenotype to a dormant-like, quiescent 
state. To confirm that loss of FASN-driven exacerbated FA 
biogenesis irreversibly re-orientates tumor cells to a stable 
and permanent commitment to differentiation, we excised 
tumor tissues from CA1d and CA1D/FASN shRNA#28-
injected animals (Figure 2) and serially transplanted them 
into mammary fat pats of athymic nude mice (Figure 4A). 
As anticipated, tumor-derived cells from CA1d control 
lesions generated fast growing tumors (Figure 4B, 4C), 
whereas tumor-derived cells from FASN-depleted lesions 
continued to form very small, slowly growing lesions that 
remained dormant for more than 30 days after injection 
(Figure 4B, 4B; Figure S4C, S4D). The histology of the 
tumors derived from transplanted cells was similar to that 
detected in the original tumors (Figure 4D). Consequently, 
CA1d control tumors displayed both highly invasive and 
proliferative phenotypes, while FASN-depleted tumors 
presented low-grade lesions with cells lining duct-
like structures resembling the morphology of normal 
mammary gland (Figure 4D). 
FASN signaling regulates subcellular structure 
proteins that demarcate the epithelial or 
mesenchymal identify of breast epithelial cells
To explore the notion that FASN signaling might 
alter hallmark EMT effector molecules that determine the 
epithelial or mesenchymal identity of a breast epithelial 
cell, we took advantage of stable sibling cell lines in which 
an EMT has been induced to stably propagate CSC-like 
enriched populations. We used experimentally transformed 
HMLER breast cancer cells (human mammary epithelial 
cells [HMECs] overexpressing hTERT, SV40 T/t and 
H-RasV12) that had been modified to inhibit expression 
of the human CDH1 (E-cadherin) gene via short hairpin 
RNA (shRNA; HMLERshECad cells), which constitutes 
a valuable method for significantly enriching cells with 
CSC-like properties [39, 40]. Quantitative real-time PCR 
(qRT-PCR) analyses revealed that the stable repression of 
the epithelial hallmark CDH1 was likewise accompanied 
by a dramatic up-regulation of vimentin (VIM) mRNA 
expression levels (> 1.000-fold) in HMLERshECad cells, a 
gene coding for an intermediate filament component of 
the mesenchymal cell cytoskeleton (Figure 5). At the same 
time, the expression of genes coding for EMT-related 
subcellular structure proteins such as fibronectin (FN1) 
and N-cadherin (CDH2) were notably increased in CDH1-
silenced HMLERshECad cells. 
A lentivirus-mediated small hairpin RNA-driven 
transient knockdown of FASN gene expression (3 days) 
was sufficient to notably reverse the overexpression of 
VIM, FN1, and CDH2. Remarkably, FASN inhibition 
almost fully reversed the exceptional high level of VIM 
expression (≈ 90% reduction) in EMT HMLERshECad cells 
(Figure 5). The ability of FASN signaling to regulate 
hallmark EMT effector molecules was confirmed by the 
full suppression of the extracellular matrix (ECM) protein 
FN1 and the significant downregulation (≈ 90% reduction) 
of the cell-surface protein CDH2 in FASN-silenced 
HMLERshECad cells. The ability of FASN inhibition to 
stably impose mesenchymal-like BC tissues to undergo 
the inverse plastic change that generates epithelial tissue 
in vivo (Figures 2–4), together with the fact that transient 
knockdown of FASN was sufficient to suppress hallmark 
structural and cytosolic/secretive proteins (vimentin, 
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N-cadherin, fibronectin) in a model of EMT-induced CSC-
like cells, strongly suggest that FASN signaling might play 
an unforeseen regulatory role in the structural configuration 
of the cytoskeleton and, hence, in determining the 
robustness of EMT vs. MET cell states (Figure 5).
Pharmacological ablation of the FASN-driven 
lipogenic phenotype reverses malignant features 
of BC stem-like cells
Although the variety of FASN inhibitors developed 
in recent years (e.g., C75, C93, C246, FAS31, Orlistat, 
triclosan, GSK837149A) has consistently demonstrated 
preclinical activity in cultured cancer cell lines and 
xenograft models, none of these compounds have 
been tested in cancer patients because of limitations 
imparted by their pharmacological properties (e.g., poor 
cell permeability, poor oral bioavailability and lack of 
selectivity) or side-effect profiles (e.g., anorexia and 
weight-loss), which could be limiting in the development 
of cancer therapy [41–43]. Because our findings might 
be explained in terms of FASN-driven maintenance of 
an undifferentiated state in stem-like cells [44–46] within 
tumor populations, we evaluated whether therapeutically 
valuable drugs with a well-known FASN inhibiting 
activity that are currently available such as the anti-
diabetic metformin [47–50] might significantly impact the 
malignant features of BC stem-like cells. 
We assessed whether metformin treatment altered 
the heterogeneity and morphology of tumorspheres 
derived from MCF10DCIS.com cells, a representative 
model of clinical comedo-ductal carcinoma in situ 
(comedo-DCIS) [51–53], a high-risk in situ breast 
lesion that might serve as precursor for basal-like BC. 
MCF10DCIS.com cells generated large, irregular solid 
spheroids that lacked a hollow lumen (Figure 6). To 
establish whether metformin was effective at altering the 
distinct basal-like mammosphere morphology comprising 
cohesive but loosely packed cells, MCF10DCIS.com were 
exposed to nanomolar concentrations of metformin over 
Figure 3: FASN depletion reduces VEGF secretion and angiogenesis in CA1d cells. (A) ELISA-based analysis of VEGF in 
the supernatant from CA1d/vector control or FASN-deficient CA1d (CA1d/FASN shRNA#28) cells. Note that FASN knockdown results in 
a significant decrease in secreted VEGF. Data from one representative experiment are presented as mean ± SD; *p = 0.02. (B) Visualization 
of vascularization in tumors from control (vector) and FASN- depleted (FASN shRNA#28) xenografts by immunohistochemical staining 
for CD34. Note the reduced vasculature in FASN-deficient tumors compared with control tumors. (C) Quantification of one representative 
experiment as described in B. Results are presented as mean ± SD; **p < 0.001. (D) FASN overexpression increases VEGF secretion in 
non-transformed MCF10 cells. ELISA of VEGF in supernatant from MCF10 vector control or FASN over-expressing cells. Data from one 
representative experiment are presented as mean ± SD; **p < 0.001.
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Figure 4: FASN depletion promotes a dormant-like phenotype as tumor-derived FASN- negative cells maintain a non-
malignant phenotype after a second passage in vivo. (A) Schematic representation of the experimental protocol to obtain second 
passage tumors. Control (CA1d/vector control) and FASN-depleted (CA1d/ FASN shRNA #28) tumor-derived cells harvested from the 
first generation transplanted tumors after 7 weeks, were grown in culture, and xenografted to form second transplant-generation tumors. 
(B) Second generation, FASN-negative tumor-derived cells are growth impaired. Orthotropic model of tumor outgrowth of the second 
transplant generation of empty vector control (CA1d/vector control) and FASN-depleted CA1d tumor-derived cells (CA1d/FASN shRNA#28) 
measured over 60 days. Data from one representative experiment are presented as mean ± SD. (C) Graph showing the distribution of tumor 
sizes of second-generation tumors in control and FASN- depleted cells 14, 21, and 28 days post injection. Results from one representative 
experiment are presented as mean ± SD (n = 10). (D) Histology (H&E stain) of second passage tumors derived from control (CA1d/
vector control) and FASN-negative (CA1d/FASN shRNA# 28) tumor-derived cells. Note that the FASN-negative cells maintain their 
non-malignant phenotype, presenting nearly normal looking ducts in contrast to the highly aggressive tumor in the control group.
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successive primary, secondary, and tertiary mammosphere 
generations. Interestingly, there was an increase in the 
number of smaller sized mammospheres relative to the 
larger ones over multiple generations of metformin-treated 
mammospheres. Moreover, the difference in the size of 
mammospheres apparently represented changes in cellular 
heterogeneity because a significant portion (up to 90%) of 
metformin-treated tertiary mammospheres became hollow 
spherical bodies composed of a single layer of epithelial 
cells surrounding an empty lumen (Figure 6). The 
drastically reduced intra-heterogeneity of tumorspheres 
occurring upon long-term exposure to clinically relevant 
concentrations of metformin, which mimicked the repeat 
dosing of drugs that patients would receive clinically, 
strongly suggest that indirect pharmacological inhibition 
of lipogenesis [47–50, 54] is sufficient to promote a switch 
from basal- to luminal-like sphere morphologies [55]. 
DISCUSSION
We here show for the first time that FASN-catalyzed 
endogenous lipogenesis is a previously unrecognized 
organizer of breast tissue architecture wherein low levels 
of FASN activation furnishes a commitment to epithelial 
Figure 5: Transient knockdown of FASN gene expression suppresses structural hallmarks of EMT. Left. Total RNA 
from HMLER, HMLERshECad, and HMLERshEcCad + shRNA FASN cells was characterized in technical triplicates for the relative abundance 
of 19 mRNAs whose levels, in published results [76, 77], are significantly altered during activation/deactivation of the EMT genetic 
program. The transcript abundance of selected EMT-related genes (VIM, FN1, and CDH2) was calculated using the delta Ct method and 
presented as fold-change vs. basal expression in HMLER cells. Right. When breast epithelial cells acquire a fibroblast-like morphology 
during EMT, they not only down-regulate the obvious effectors of the epithelial phenotype such as E-cadherin (CDH1), but also switch 
the expression of an entire battery of genes including those that encode mesenchymal intermediate filaments (e.g., cytokeratins à vimentin 
switch) and ECM proteins (e.g, fibronectin, FN1). The status of FASN signaling appears to coincide with a self-reinforcing attractor 
(see Figure 7) in the structural configuration of the breast epithelial cell cytoskeleton, thus explaining that the sole correction of exacerbated 
lipogenesis can stably reprogram the malignant, invasive phenotype of cancer cells back to normal-like tissue architectures.
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differentiation and increased FASN activation drives 
architectural destruction of breast tissue and progression 
to malignancy. Our results demonstrate not only that 
misregulation of lipogenic metabolism plays a causal role 
in progression of malignancy in human breast epithelial 
cells, but also that correction of exacerbated lipogenesis 
is sufficient to restore a normal-like tissue form and 
function and suppress tumorigenicity of metastatic BC cells 
in vivo. Thus, analogous to the epigenetic suppression of 
malignancy following retinoid treatment of leukemias, 
manipulation of endogenous lipogenesis can override the 
unstable cancer genome in metastatic tumor cells, offering a 
plausible alternative therapeutic modality of differentiation 
therapy for BC and other solid epithelial tumors. 
A survey of the genomic alterations in the isogenic 
MCF10 model of BC progression, from non-malignant 
MCF10A cells to pre-invasive DCIS.com cells and invasive 
CA1 cells, has recently revealed hundreds of coding 
mutations in multiple cancer driver genes commonly 
found in primary BC (e.g., PIK3CA and TP53) [56]. 
These mutations change the expression of genes 
involved in proliferation and adhesion, and in signaling 
pathways such as Wnt and MAPK, as well as the gain 
of copy-number alterations associated with cancer 
progression (e.g., deletion of RUNX1, a lineage 
specific master regulator controlling mammary luminal 
cell fate). In this setting, our discovery of FASN as a 
negative regulator of tissue architecture and terminal 
epithelial cell differentiation, which is dominant over the 
malignant phenotype of metastatic tumor cells possessing 
multiple cancer-driving genetic lesions [28, 56], points 
to an unappreciated role for endogenous lipogenesis 
in controlling a supra-genetic dimension critical to 
tumorigenesis. That the correction of a metabolic 
cue, such as endogenous lipogenesis, can reverse the 
malignant behavior of mesenchymal-like metastatic BC 
cancer tissues to recover normal tissue architecture in a 
genome background that is malignant and unstable due to 
bona fide cancer-driving genetic abnormalities, obliges a 
consideration of a conceptual Waddingtonian framework 
of system-level dynamics based on a “state space” model 
of self-organizing “attractors” (i.e., phenotypes), instead 
of the mainstream genetic determinism that underlies 
the most commonly claimed models of metastatic 
progression [57–59]. Furthermore, the ability of FASN to 
dictate the organizational phenotype of breast tissue and 
the fate of normal and neoplastic epithelial cells might 
not be satisfactorily explained exclusively in terms of 
reprogrammed phenotypes (i.e., mesenchymal versus 
epithelial) or behaviors (metastatic versus non-invasive) 
at the cellular level. That is, solely a model of “attractor 
switching” applied to interactions at the tissue level [60] 
can clarify how the suppression of lipogenic signals is 
sufficient to guide genetically-aberrant metastatic tumor 
tissues to a near normal phenotype in terms of organized 
and polarized epithelial structures with low proliferation 
index and angiogenic shut off. Even subtle changes in 
FASN-driven endogenous lipogenesis may translate to a 
change in the attractor landscape with major biological 
consequences if the induced network rewiring results 
in shifts of attractor boundaries and shapes (Figure 7). 
Correction of exacerbated lipogenesis can cause a 
Figure 6: Indirect pharmacological inhibition of FASN promotes a phenotypic switch in breast tumorsphere architecture. 
Left. Figure shows representative light microscope representations of 3rd generation mammospheres formed by MCF10DCIS.com cells 
growing in sphere medium in the absence or presence of graded concentrations of metformin, as specified (20× magnifications). Right. 
Quantification of the hollow (luminal-like) and filled/mass (basal-like) morphologies occurring in untreated and metformin-treated P3 
mammospheres. Note that long-term exposure to clinically relevant nanomolar concentrations of the indirect FASN inhibitor metformin 
reduces the intra-sphere heterogeneity and promotes a switch from basal- to luminal-like sphere morphologies, suggesting promotion of a 
luminal differentiation axis and/or reversion of the basal/mesenchymal state.
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Figure 7: FASN-regulated phenotype of breast cancer tissues. A Waddingtonian perspective. Schematic visualization of the 
principle that FASN-regulated network rewiring causes a distortion of the attractor landscape (i.e., tissue architecture) that results in shift of 
attractor boundaries and allows a non-genetic switching between discrete phenotypic states (i.e., N: Normal; M: Malignant). Top. Despite 
schematic reduction of dimensionality, the developmental trajectory on the Waddingtonian epigenetic surface is established by “tissue 
states”, which are defined not only by gene-gene network interactions at the cellular level but rather extends beyond to include changes 
in the cell-cell interaction network including neovascularization and alterations in ECM turnover and mechanics. The status of FASN 
activation (vertical arrows) causes a normal tissue to become proliferative and mesenchymal by placing the tissue state (black circle) within 
the metastatic basin of attraction (red, top panel). Upon FASN inhibition, the non-proliferative and epithelial attractor (blue, bottom panel) 
is enlarged at the cost of the metastatic attractor (red), which shrinks as a consequence of the suppression of FASN. Bottom. Suppression of 
FASN-driven endogenous lipogenesis is sufficient to toggle the metastatic phenotype back to the original state by acting as a controller of 
attractor switching between self-propelling and self-stabilizing tissue states irrespective of genetic alterations.
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distortion of the attractor landscape that easily allows 
cells in a given tissue organization attractor that encode 
a proliferative, mesenchymal-like undifferentiated 
phenotype, to suddenly acquire a new phenotype by 
placing them in a self-stabilizing attractor encoding 
a quiescent, mature epithelial-like tissue phenotype. 
Conversely, upon activation of FASN-driven endogenous 
lipogenesis, an a priori inaccessible attractor encoding 
the mesenchymal-like undifferentiated tissue phenotype 
can suddenly become easily accessible to cells originally 
placed in the self-stabilizing attractor of terminal tissue 
differentiation. Because cellular plasticity is at the center 
of phenotypic reversion of the malignant phenotype, 
which is also linked to the concept of tumor cell stemness, 
it is formally possible that the activation status of FASN 
might dictate the degree of refractoriness of breast 
epithelial cells to differentiation and, therefore, their 
intrinsic susceptibility to the epigenetic rewiring required 
for the activation of a pathological differentiation program 
of aberrant stemness. 
Mutational and epigenetic changes in oncogenes 
and tumor suppressor genes have been investigated 
exhaustively during the past decades as the main molecular 
players involved in the maintenance of tissue homeostasis 
and, consequently, of normal versus cancerous 
organization and/or non-metastatic versus metastatic 
behavior. Nonetheless, largely unknown extracellular 
and/or intracellular cues not necessarily dependent on 
(epi)genetic alterations can drastically impact the intrinsic 
developmental uncertainty of tissues, promoting cell 
fate switching by an asymmetric amplification of certain 
processes and events to be initiated at the correct site 
and appropriate time (e.g., normal tissue morphogenesis 
and functional differentiation), in conjunction with long-
range inhibition of pathological developmental programs 
(e.g., dedifferentiation and loss of tissue architecture). 
The pathways that regulate cell architecture and tissue 
organization are, unfortunately, poorly understood and 
have been largely disregarded by biomedical scientists 
and clinicians as a means to identify molecular targets for 
long-term management of human carcinomas. Moreover, 
the majority of studies have focused on the role of 
signaling emanating from the extracellular matrix (ECM) 
as the ultimate regulator of tissue architecture and, hence, 
of epithelial function. In this regard, landmark 3D culture 
modeling approaches from the Bissell group have elegantly 
demonstrated the feasibility of phenotypically altering the 
ECM to dramatically modify the differentiation state of 
invasive tumor cells to one resembling a more normal 
cell phenotype irrespective of the genetic abnormalities 
in the tumor cells [61–67]. Here, we have mimicked the 
ability of cell surface ECM-receptor manipulations to 
abrogate malignancy and revert the tumor phenotype to a 
near-normal phenotype by suppressing cancer-associated 
overactive endogenous lipogenesis [68, 69].  Our findings 
confirm the notion that several canonical signaling 
pathways are indeed intrinsically and reciprocally linked 
within the morphological normal form, irrespective of 
the strategy used. Our results corroborate recent studies 
showing that blocking FASN-driven lipid synthesis 
efficiently overcomes tumor regrowth and metastasis 
after antiangiogenic therapy withdrawal [70]. We cannot 
exclude the possibility that the ability of FASN to regulate 
tumor vasculature through alteration not only of the profile 
of secreted angiogenic factors, but also of expression 
and activity of key regulators of tissue architecture such 
as matrix metalloproteinases (e.g., MMP-9) [71], might 
establish a dynamic reciprocity between FASN-driven 
endogenous lipogenesis, tissue polarity (e.g., changes 
in intermediate filaments such as the EMT-related 
cytokeratin-to-vimentin switch), ECM integrity, and 
angiogenesis, thus providing an axis for either tissue 
homeostasis or malignant progression [72–74]. Although 
it might appear counterintuitive, the “easy” way by which 
tissues switch between the mesenchymal and epithelial 
phenotypes in response to changes in the activation status 
of FASN might reveal that, in Waddingtonian terms, 
an “attractor” in the biochemical gene activity profile 
(e.g., FASN-regulated effectors of epithelial phenotype) 
is coincidental with a self-reinforcing “attractor” in 
the structural configuration of the cytoskeleton, thus 
explaining the robustness of phenotypic reversion and 
normalized differentiation that occurs in response to FASN 
suppression in metastatic cancer cells. 
Our current findings establish FASN as a critical 
link between cell metabolism and the control of tissue 
architecture, the elucidation of which could have an 
important impact on targeted therapy for malignancies 
of the breast. Indeed, the fact that sole correction of 
FASN upregulation, one of the most common and 
earliest metabolic changes in human malignancies 
that is not caused by mutational or gene amplification 
events, can reprogram metastatic cancer cells to stably 
recover normal-like tissue architecture, might open a 
new avenue to chronically restrain the life-threatening 
potential of metastatic carcinomas by using FASN-based 
differentiation therapies. 
MATERIALS AND METHODS
Cell lines, cell culture and reagents
MCF10A, MCF10NeoT, MCF10AT1 and 
MCF10A1kcl2 cells were cultured in DMEM/Ham’s 
F-12 (DMEM/F-12) supplemented with 5% horse serum 
(HS), 10 mM HEPES, 10 ng/ml insulin, 20 ng/ml EGF, 
100 ng/ml cholera toxin, and 0.5 mg/ml hydrocortisone. 
MCF10ADCIS, MCF10CA1a (CA1a), MCF10CA1b 
(CA1b), and MCF10CA1d (CA1d) cells were cultured 
in DMEM/F-12 with 5% HS. Cells were maintained at 
37 °C in a humidified atmosphere of 95% air and 5% 
CO2. Cells were authenticated to ensure their identity 
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using the short tandem repeat profiling method provided 
by the Genotyping Shared Resource, Mayo Clinic 
(Rochester, MN). Cells were regularly tested to confirm 
the absence of mycoplasma using the MycoAlert™ 
mycoplasma detection kit (Lonza, Walkersville, MD). 
Generation of stable cell lines
MCF10CA1a and MCF10CA1d cells (12 000/
well) were seeded in 24-well plates in DMEM containing 
10% fetal bovine serum. After 24 h, cells were washed 
with PBS and the medium was changed to DMEM/F12 
containing 5% HS and 8 µg/ml polybrene. Cells were then 
infected with the lentiviral pLKO.1 vector (vector control) 
or pLKO.1 vector carrying shRNA targeting FASN 
at MOI = 5 (TRCN0000003126, TRCN0000003127, 
TRCN0000003128 and TRCN0000003129) or with 
lentiviral transduction particles expressing a control 
scramble shRNA (MISSION, Sigma, Burlingame, CA). 
After transduction, the medium containing the lentivirus 
was replaced with fresh medium containing puromycin 
(0.75 μg/ml) as a selection marker.
Western blotting
Equal amounts of protein (10 μg) were resolved 
on 10% Criterion XT Bis-Tris Precast Gels (Bio-Rad, 
Hercules, CA) and transferred to PVDF membranes. 
Membranes were blocked with TBS-T (TBS and 0.5% 
Tween 20) containing 5% (w/v) non-fat dry milk or 5% 
BSA (depending on the primary antibody) for 30 minutes 
to 1 h and washed with TBS-T. Membranes were then 
incubated overnight at 4oC with different antibodies 
including FASN (clone 23, BD Biosciences, Pharmingen), 
p21 (F-5, Santa Cruz Biotechnologies, Santa Cruz, CA) 
and AMPK, p-AMPK, ACC and p-ACC (Cell Signaling 
Technology, Danvers, MA). After a further 3 washes with 
TBS-T, membranes were incubated with horseradish 
peroxidase-linked secondary antibodies. Blots were then 
stripped and re-probed with a monoclonal antibody to 
β-actin and horseradish peroxidase-linked goat anti-mouse 
IgG secondary antibody. Proteins were detected by an 
enhanced chemoluminescence reaction using Hyperfilm 
(Amersham-Pharmacia, Piscataway, NJ). 
Cell viability assay
Cell viability was determined with the MTT (3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
reduction assay. Briefly, cells (4 × 103 /well) were seeded 
into 96-well plates and allowed to attach for 16 h. After 
a PBS wash, fresh medium containing cerulenin or C75 
in various concentrations was added. Three days after 
treatment, the cells were washed, supplied with fresh 
medium containing 15 μl of MTT dye and then incubated 
for 4 h at 37°C. The reaction was stopped by addition 
of 100 µl solubilizing solution/stop mix and the plates 
were incubated overnight at 37°C. The following day, the 
absorbance at 570 nm was measured in each sample using 
a multiwell plate reader (Victor ×3, PerkinElmer) and the 
cell viability was assessed using the equation: (A570 of 
Cerulenin or C75 treated sample/A570 of vehicle-treated 
sample) × 100.
In vitro growth assays
Anchorage-dependent growth assay:  Cells (5 × 103/
well) were seeded into 24-well plates (Cellstar, Greiner 
Bio-One) in DMEM/F-12 supplemented with 5% HS. 
After 24 hours, cells were counted (= day 0) and counting 
was continued each day for 4 days using the Vi-cell XR 
cell counter and viability analyzer (Beckman Coulter, CA). 
Anchorage-independent growth assay: A bottom layer of 
1.5 ml DMEM/ F-12 medium containing 0.6% agar and 
5% HS was prepared in 6-well plates. After the bottom 
layer solidified, cells were suspended in a 1 ml top layer 
of DMEM/F-12 medium containing 0.35% agar and 5% 
HS. Plates were then incubated in a humidified 5% CO2 
incubator at 37°C. After 9–14 days, colonies larger than 
50–70 µm in diameter were counted with an automatic 
colony counter (Gel Count, Oxford Optronix, UK). 
Three-dimensional (3D) basement membrane 
assay
Cells were cultured using a 3D overlay method as 
described [75]. Briefly, cells were seeded (3000 cells/well) 
on a solidified layer of growth factor-reduced Matrigel 
(BD Bioscience) measuring approximately 1–2 mm 
in thickness in an 8-well chamber slide. The cells were 
overlaid with DMEM/F12 medium containing 5% HS and 
2% Matrigel and grown for 6 days. 
Indirect immunofluorescence
Staining was performed as described for MCF10A 
acini cultured in Matrigel [75] using anti E-cadherin 
(BD Transduction Laboratories) as primary antibody and 
Alexa-488 conjugated anti-mouse from Molecular Probes 
as secondary antibody. Nuclei were visualized using 
DAPI. 
Animal studies
Two million cells (cell type as indicated in the 
description for each experiment) in 1:1 PBS/Matrigel 
(10 mg/ml, BD Bioscience) were injected into the 
mammary fat pad of 3–4-week-old female athymic nude-
Foxn1nu mice (Harlan, Indianapolis, IN). Tumor volume 
was calculated by 3D measurements using the formula: 
Tumor volume (mm3) = length × width × height
 2
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Tumor measurements were performed weekly using 
a Vernier caliper. Mice were sacrificed before the tumor 
volume reached ~ 2 cm3. Mice were then euthanized, 
tumors were excised, fixed in formalin, and embedded 
in paraffin. Paraffin-embedded tumor sections were then 
prepared and stained with hematoxylin and eosin for 
histopathology analysis. Tumor measurement was blinded 
to minimize experimental bias. Additional sections were 
generated for immunohistochemical analysis. The Mayo 
Institutional Animal Care and Use Committee approved 
the animal protocols.
Preparation of tumor-derived cells
CA1d/vector control or CA1D/FASN siRNA tumors 
grown in the mammary fat pad of athymic nude mice for 
7 weeks were cut in small pieces, incubated in a trypsin 
solution at 37°C for 10 minutes and resuspended in 10 ml 
of culture medium. Cells were collected by centrifugation 
at 400 g for 5 minutes and plated on a collagen-coated 
dish. Cells were cultured in DMEM/F-12 with 5% HS, 
penicillin (100 units/ml), streptomycin (100 μg/ml), 
puromycin (1 μg/ml) and amphotericin B (2.5 μg/ml) 
at 37°C in a humidified 5% CO2 atmosphere until they 
reached 70% confluence, after which they were re-plated 
in Petri dishes without collagen. After two weeks of 
culture, the expression of FASN in tumor-derived cells 
was evaluated by western blotting. 
VEGF production measured by ELISA
Cells (2 × 105/well) were seeded in 6-well plates 
and cultured in complete growth medium. After reaching 
~70% confluence, cells were washed twice with PBS and 
the medium was changed to serum-free medium (SFM). 
After 24 hours of serum starvation, culture media was 
collected, centrifuged at 1100 g for 10 minutes at 4°C 
and the supernatant was tested for VEGF immediately 
or stored at −80°C until analysis. VEGF protein was 
determined using the VEGF ELISA Kit (Peprotech, 
Rocky Hill, NJ). Absorbance was measured at 405 nm in 
an ELISA reader (Bio-Tek Instruments, Winooski, VT). 
Immunohistochemical analysis
Paraffin sections were deparaffinized at 60°C for 
60 minutes. For Ki-67 and E-cadherin detection, slides 
were subjected to heat-induced epitope retrieval (HIER) 
in a decloaking chamber (Biocare Medical, Concord, CA) 
with Target Retrieval solution, pH 6.0 (DakoCytomation, 
Glostrup, Denmark). Antigen retrieval for FASN was 
performed with 10 mM sodium citrate, pH 6.0 for 
20 minutes at 95°C and citrate-EDTA buffer (10 mM Citric 
Acid, 2 mM EDTA, pH 8 was used for CD34. Endogenous 
peroxidase activity was blocked with 3% hydrogen 
peroxide for 5 min. Non-specific binding sites were 
blocked using PBS-T (PBS 0.01 M, triton ×−100 0.1%, 
Tween 20 0.05%) containing 1% BSA and 5% HS.  Slides 
were exposed for 1.5 hours at room temperature to either 
rabbit polyclonal anti-Ki-67 (Fisher) or rabbit polyclonal 
anti-E-Cadherin (Cell Signaling). Sections were incubated 
at 4°C overnight with anti-FASN Rabbit IgG1 (IBL) or 
anti-mouse CD34 Rat IgG1 (BD Pharmingen). Thereafter, 
the slides were rinsed three times with PBS and incubated 
with the corresponding secondary antibodies (anti-rabbit 
or anti-mouse biotin-labeled; DakoCytomation) followed 
by streptavidin–biotin–peroxidase for 30 minutes at room 
temperature. Immunostaining was visualized using the 
DAB+ Kit (DakoCytomation). Slides were counterstained 
using Gill’s haematoxylin. Microvessels were identified by 
immunostaining with rat anti-mouse polyclonal antibody 
CD34. The entire section was scanned systematically at 
low magnification (×100) to identify the most intense 
areas of neovascularization (“hotspots”) within the tumor. 
After five hotspots areas with the highest number of 
capillaries and small venules were identified, microvessels 
were counted at high power magnification (×400) and the 
average count in five fields was calculated.
Immunofluorescence analysis
Paraffin sections were deparaffinized at 60°C for 
60 minutes; antigen retrieval and blocking was performed 
as described for the immunohistochemical analysis. Anti-
FASN antibody was used as described above and the anti-
SMA mouse monoclonal antibody (Dako) was diluted in 
PBS containing 3% non-fat dry milk. After three washes in 
PBS, the signal was detected by a combination of the anti-
rabbit FITC (green) and the anti-mouse TRITC antibodies 
(red, Sigma). 
Quantitative real-time polymerase chain reaction 
(qRT-PCR)
The total RNA was extracted from cell cultures using 
a Qiagen RNeasy kit and QIAshredder columns according 
to the manufacturer’s instructions. One microgram of total 
RNA was reverse-transcribed to cDNA using the Reaction 
Ready™ First Strand cDNA Synthesis Kit (SABiosciences) 
and applied to a customized PCR array (96-well format) 
containing the following panel of genes: GSC, KRT14, 
KRT19, NUMB, TCF3, TCF4, SDC1, ZO-1, CD44, 
TWIST, SNAI1, VIM, SLUG, CDH1, ZEB1, CDH2, ZEB2, 
FN1, and CD24. The arrays were processed according to 
the SABiosciences RT-PCR manual and analyzed using 
an Applied Biosystems 7500 Fast Real-Time PCR System 
with an automated baseline and threshold cycle detection. 
The data were interpreted using SABiosciences’s web-
based PCR array analysis tool.
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Lentiviral transduction
Pre-packaged lentiviral particles that either encoded 
a non-targeting shRNA (negative shRNA, sc-108080) or 
sequences specifically targeting the human FASN gene 
(sc-43758-V; Lot#B2610) were purchased from a 
commercial provider (Santa Cruz Biotechnology). For 
viral infection of HMLERshECad cells, the regular medium 
was replaced with culture medium containing 5 µg/mL 
polybrene (Santa Cruz Biotechnology, sc-124220). Cells 
were then exposed to lentiviruses for 48 h. The cells 
were then washed and grown in regular médium for an 
additional 24 h. 
Mammosphere culture and mammosphere-
forming efficiency
Single cell suspensions (1000 cells/mL) were plated 
in 6-well tissue culture plates previously coated with poly-
2-hydroxyethyl-methacrylate (Sigma, St. Louis, MO) 
to prevent cell attachment, in serum-free DMEM/F-12 
supplemented with 1% L-glutamine, 1% penicillin/
streptomycin, 2% B27 (Invitrogen, Carlsbad, CA), 20 ng/
mL EGF (Sigma) and 20 ng/mL FGFb (Invitrogen). The 
medium was made semi-solid with 0.5% methylcellulose 
(R&D Systems, Minneapolis, MN) to prevent cell 
aggregation. 
Nonadherent spherical clusters of cells, named P1, 
were collected after 7 days and disaggregated using 
enzymatic and mechanical dissociation. P1-derived 
single-cell suspensions were seeded again at 1000 cells/
mL to generate nonadherent spherical clusters of cells, 
named P2, and the process was repeated at third time to 
generate P3. This procedure was performed in the absence 
or presence of graded concentrations of metformin (0, 10, 
and 100 nmol/L). Mammosphere-forming efficiency 
(MSFE) was calculated as the number of sphere-like 
structures (diameter > 50 μm) formed by P1, P2, and P3 
cells divided by the original number of cells seeded, and 
expressed as a percentage.
Statistical analyses
The quantitative data were collected from at least 
three independent experiments performed in triplicate and 
the data from one representative experiment are presented 
as mean ± S.D. For comparisons between two populations, 
an unpaired two-tailed Student’s t test was performed from 
three independent experiments, unless otherwise specified. 
Statistical analysis was performed with GraphPad Prism 
5.01 or Microsoft Office Excel software. Differences were 
considered significant when the p values were < 0.05.
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